Enlivex Therapeutics Ltd. is mixing biotech with blockchain.
Abstract
- Enlivex Therapeutics raised $212 million by means of a personal fairness deal and is utilizing a lot of it to construct a digital asset treasury by way of the RAIN token, a decentralized prediction market protocol.
- The corporate holds roughly 76 billion RAIN tokens and an possibility to purchase practically $918 million extra at a deep low cost, which analysts say may create a significant unpriced worth driver.
- In the meantime, its osteoarthritis remedy Allocetra continues to indicate promising ends in scientific trials. HC Wainwright reaffirmed a Purchase ranking on Enlivex and raised its 12-month value goal to $13, citing each the RAIN token technique and scientific progress.
The clinical-stage firm, identified for its osteoarthritis drug Allocetra, final 12 months raised $212 million in a personal fairness deal and is now deploying a big portion of the proceeds to construct a digital asset treasury anchored in prediction markets.
The transfer facilities on the RAIN token, a totally decentralized prediction and choices protocol on the Arbitrum community. Enlivex bought 212 million RAIN tokens at $1 per share, funded in a mixture of U.S. {dollars} and USDT, utilizing them to implement what the corporate calls its first RAIN token treasury technique.
The RAIN platform permits anybody to create and commerce customized markets, with outcomes resolved by way of AI and ruled by a deflationary buy-and-burn token mechanism.
RAIN undervalued
HC Wainwright & Co.’s Raghuram Selvaraju flagged the token as undervalued, noting that Enlivex’s holdings of roughly 76 billion RAIN tokens—plus an possibility to purchase practically $918 million extra at $0.0033 per token—may create a future worth driver at the moment unpriced by the market.
Since its launch in September 2025, RAIN has seen $1.5 billion in buying and selling quantity over 3.5 months, with each day volumes averaging $55 million. Analysts cite precedent tasks reminiscent of Polymarket and Kalshi, which reached an $11 billion valuation, as proof of the expansion potential in decentralized prediction markets.
Enlivex isn’t leaving its biotech ambitions behind. Allocetra continues to indicate promising ends in osteoarthritis trials, with six-month information demonstrating substantial ache discount and purposeful enchancment in sufferers aged 60 and older. Extra research in basal thumb osteoarthritis are anticipated to report top-line ends in the approaching months.
HC Wainwright reiterated a Purchase ranking on Enlivex, elevating its 12-month value goal to $13 per share, citing each the potential of the RAIN token treasury and ongoing scientific progress with Allocetra.
